1. Home
  2. TMQ vs CBLL Comparison

TMQ vs CBLL Comparison

Compare TMQ & CBLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trilogy Metals Inc.

TMQ

Trilogy Metals Inc.

HOLD

Current Price

$3.74

Market Cap

705.7M

ML Signal

HOLD

Logo CeriBell Inc.

CBLL

CeriBell Inc.

HOLD

Current Price

$17.84

Market Cap

750.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TMQ
CBLL
Founded
2004
2014
Country
Canada
United States
Employees
N/A
280
Industry
Precious Metals
Sector
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
705.7M
750.1M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
TMQ
CBLL
Price
$3.74
$17.84
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$23.20
AVG Volume (30 Days)
2.4M
240.0K
Earning Date
04-02-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$29.57
Revenue Next Year
N/A
$28.44
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.30
$10.85
52 Week High
$11.29
$24.33

Technical Indicators

Market Signals
Indicator
TMQ
CBLL
Relative Strength Index (RSI) 41.63 45.47
Support Level $3.35 $17.11
Resistance Level $4.53 $19.56
Average True Range (ATR) 0.28 0.82
MACD -0.04 -0.00
Stochastic Oscillator 13.64 35.89

Price Performance

Historical Comparison
TMQ
CBLL

About TMQ Trilogy Metals Inc.

Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the USA. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.

About CBLL CeriBell Inc.

CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.

Share on Social Networks: